Antimycobacterial effect of selenium nanoparticles on mycobacterium tuberculosis

Tuberculosis (TB) remains the leading cause of death from a single infection agent worldwide. In recent years, the occurrence of TB cases caused by drug-resistant strains has spread, and is expected to continue to grow. Therefore, the development of new alternative treatments to the use of antibioti...

Descripción completa

Detalles Bibliográficos
Autores: Estevez, Hector, Palacios, Ainhoa, Gil, David, Anguita, Juan, Vallet-Regi, Maria, González, Blanca, Prados Rosales, Rafael Carlos, Luque-Garcia, Jose L.
Tipo de recurso: artículo
Fecha de publicación:2020
País:España
Institución:Universidad Autónoma de Madrid
Repositorio:Biblos-e Archivo. Repositorio Institucional de la UAM
Idioma:inglés
OAI Identifier:oai:repositorio.uam.es:10486/693943
Acceso en línea:http://hdl.handle.net/10486/693943
https://dx.doi.org/10.3389/fmicb.2020.00800
Access Level:acceso abierto
Palabra clave:antimycobacterial effect
cell wall damaging agents
mycobacterium tuberculosis
selenium nanoparticles
smegmatis
Medicina
Descripción
Sumario:Tuberculosis (TB) remains the leading cause of death from a single infection agent worldwide. In recent years, the occurrence of TB cases caused by drug-resistant strains has spread, and is expected to continue to grow. Therefore, the development of new alternative treatments to the use of antibiotics is highly important. In that sense, nanotechnology can play a very relevant role, due to the unique characteristics of nanoparticles. In fact, different types of nanoparticles have already been evaluated both as potential bactericides and as efficient drug delivery vehicles. In this work, the use of selenium nanoparticles (SeNPs) has been evaluated to inhibit the growth of two types of mycobacteria: Mycobacterium smegmatis (Msm) and Mycobacterium tuberculosis (Mtb). The results showed that SeNPs are able to inhibit the growth of both types of mycobacteria by damaging their cell envelope integrity. These results open a new opportunity for the use of this type of nanoparticles as antimycobacterial agents by themselves, or for the development of novel nanosystems that combine the action of these nanoparticles with other drugs.